



寒春風起
美意如春
水如如如
不盡
意

Cold Spring Harbor Asia



Tumor Immunology and Immunotherapy

Suzhou, China October 28 - November 1, 2013

Abstract Deadline: September 16, 2013

Registration Deadline: October 28, 2013

Web: www.csh-asia.org

Email: meetings@csh-asia.org

Tel: +86-512-62729029

Organizers:

Xuetao Cao, Chinese Academy of Medical Sciences, China
Xin-Yuan Fu, National University of Singapore, Singapore
Olivera Finn, University of Pittsburgh School of Medicine, USA
Cornelius Melief, Leiden University Medical Center, The Netherlands

Major Topics:

- Cancer vaccines
- Antibody therapy
- Adoptive T cell therapy
- Combination of immunotherapy with other therapies
- Cancer, inflammation and immunosuppression
- Immune escape of cancer
- Aging, immunity and cancer
- Oncogenic viruses, immunity and immunotherapy

Keynote Speakers:

David Baltimore, California Institute of Technology, USA
Engineering Immunologic Protection and Therapy
Xiaodong Wang, National Institute of Biological Sciences, China
TNF α and TLR3/4 induced necrosis pathway

Invited Speakers:

Jean Pierre Abastado, Singapore Immunology Network, Singapore
Cancer cells hijack immune cells for dissemination and metastasis
Jay Berzofsky, National Cancer Institute, USA
Cancer Vaccines: Basic strategies and clinical translation
Jannie Borst, The Netherlands Cancer Institute, The Netherlands
Mechanistic insights in T-cell costimulation by the CD27/CD70 pathway encourage application in cancer immunotherapy
Vincenzo Bronte, University of Verona, Italy
Molecular and metabolic control of adaptive immunity by tumor-induced myelopoiesis
Xuetao Cao, Chinese Academy of Medical Sciences, China
New cell subsets in tumor immune escape and metastasis
Yuan Chang, University of Pittsburgh Cancer Institute, USA
Merkel cell polyomavirus: a model in tumorigenesis and immunity
Liping Chen, Yale School of Medicine, USA
Inhibiting co-inhibitors for immunotherapy of cancer
Olivera Finn, University of Pittsburgh School of Medicine, USA
Disease associated antigens as targets for cancer immunosurveillance and candidates for prophylactic cancer vaccines
Xin-Yuan Fu, National University of Singapore, Singapore
An Inducible Cancer Metastatic Niche Mediated by Endothelial STAT3
Yang-Xin Fu, The University of Chicago, USA
Changing tumor microenvironment by local ablative radiation and

modified antibody for better immunotherapy
Yukai He, Georgia Regents University Cancer Center, USA
Engineering epitope-optimized AFP-based gene vaccines to prevent autochthonous hepatocellular carcinoma
Erica Jensen Jarolim, Medical University Vienna, Austria
Comparative oncology: Development of xenogenic vaccines and recombinant antibodies for dog mammary cancer patients.
Dieter Kabelitz, University of Kiel, Germany
Towards improving immunotherapeutic strategies with human gamma/delta T-cells
Yutaka Kawakami, Keio University School of Medicine, Japan
Different tumor immunoenvironments among patients and their modification by molecular targeted therapy
Binfeng Lu, University of Pittsburgh School of Medicine, USA
Danger signal IL-33 and antitumor Immunity
Ignacio Melero, University of Navarra, Spain
Unfolding CD137-based cancer immunotherapy
Cornelius Melief, Leiden University Medical Center, The Netherlands
TLR-ligand peptide conjugates for superior therapeutic vaccination against immunogenic cancers
Ira Mellman, Genentech, USA
Oncology meets immunology: targeting PD-L1 in combination
Andrew Mellor, Georgia Regents University, USA
A Tale with a STING: Pivotal pathways that control immune responses to DNA
Graham Pawelec, University of Tuebingen Center for Medical Research, Germany
Immunosenescence and cancer
Zihai Qin, Chinese Academy of Sciences, China
S100A4(FSP-1) promotes liver fibrosis and hepatocellular carcinoma
Michel Sadelain, Memorial Sloan-Kettering Cancer Center, USA
Targeting tumors with genetically enhanced T lymphocytes
Mark Smyth, Queensland Institute of Medical Research in Brisbane, Australia
Receptor ligand interactions that regulate tumor growth and metastases
Rong-Fu Wang, The Methodist Hospital Research Institute Houston, USA
Innate signaling and antigen-specific cancer immunotherapy
Cassian Yee, UT MD Anderson Cancer Center, USA
Adoptive T Cell Therapy of Cancer: Age of Renaissance
Hua Yu, City of Hope Duarte, USA
Pathways to Targeting STAT3: Transition into the Clinic
Limin Zheng, Sun Yat-sen University, China
Macrophage Plasticity in Distinct Microenvironments of Human Tumors
Weiping Zou, University of Michigan Medical School, USA
Immune elements shape cancer stemness